CBD Combined With Essential Fatty Acids Is 40% More Efficient In Epilepsy Seizure Reduction Than Regular CBD, New Study

CANAQUEST MEDICAL CORP CANQF, a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system, announced statistically significant efficacy results from the clinical dose and efficacy study conducted by Dr. W McIntyre Burnham, emeritus professor of the University of Toronto's Temerty Faculty of Medicine. In comparison to standard CBD, CQ-001 (cannabidiol "CBD" + IP formula - essential fatty acids) demonstrated 40% more seizure reduction at a medium dose in the maximal electroshock seizure model. This result indicates that CQ-001 is stronger than standard CBD, and could be used a lower dose to achieve seizure control.

Highlights derived from the study are as follows:

  • The enhanced efficacy from these clinical studies further validates the pre-clinical trial results obtained by Dr. Steven Laviolette, a professor and neuroscientist, at Western University.

  • These results set the stage for substantially smaller dosages of CBD generating the desired results without the negative side effects and will define a dosage of CQ-001 for a clinical trial (phase II/III, double-blind trial, 60 patients).

  • CanaQuest has identified the regulatory pathways to obtain Rx drug identification numbers in Canada and the USA for epilepsy rare neurological conditions. CQ-001, in combination with its proprietary processing and delivery method, is estimated to be approved in about 3 years.

"Further testing will be necessary, however preliminary tests suggest that CQ-001 is stronger than regular CBD," stated Burnham, pharmacologist and co-director of EpLink.

Paul Ramsay, president, stated, "The clinical study results reconfirm the pre-clinical trial results conducted at Western University, and further substantiate the magnitude of this life-changing discovery."

Get your daily dose of cannabis news on Benzinga Cannabis. Don’t miss out on any important developments in the industry.

Photo by Jeff W on Unsplash

 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis is evolving – don’t get left behind!

Curious about what’s next for the industry and how to leverage California’s unique market?

Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!

Get your tickets now to secure your spot and avoid last-minute price hikes.